Navigation Links
TECNALIA investigates advanced biomaterials to make more reliable and hardwearing medical implants
Date:11/12/2008

The TECNALIA Technological Corporation is taking part in the Cnit Intelimplant project, the goal of which is to develop advanced biomaterials based on innovative technologies (microtechnologies, nanotechnologies, tissue and surface engineering) for the manufacture of a new generation of implants which have greater durability and reliability, need less recuperation time and that provide data on their state and progress.

The Cnit Intelimplant project (Development of Advanced Biomaterials for a New Generation of Implants), led by the Biotechnology Institute (BTI), was one of the 16 projects approved by the Centre for Industrial Technological Development (CDTI) for the third CNIT programme announcement or call, within the Spanish Government INGENIO 2010 initiative.

The end goal of the project is the development of novel biomaterials which enable an extension of the functions of the implant throughout the whole life of the patient, in such a way that repeat surgical operations are avoided; the reliability and the integration of the implants are enhanced and tissue rejection avoided; the recuperation times for patients are significantly cut and the implants are operational in a minimum time; the state and progress of the implant monitored, both in the short term and in the long term after the surgical operation; the new materials will indicate any anomaly and enable the application of preventative therapies; and finally, they will simplify surgical practice, progressing to minimally invasive surgery and the automation of stages during an operation.

The project will be undertaken by a consortium made up of 15 companies, including state-of-the-art Spanish enterprises in the field of implants, BTI Biotechnology Institute, SURGIVAL, LAFITT, SOCINSER and IHT, as well as the most important ones in the value chain of their manufacture: KERAMAT, Laboratories INIBSA, BIOKER Research, METAL-ESTALKI, BIOVAC, DMP, i2m-DESIGN, ANLISIS & SIMULACIN (AyS), IHS WEIGLING and GEM-IMAGING.

The Intelimplant project involves groups belonging to 16 public and private research bodies: TECNALIA, the Institute of Biomechanics of Valencia-IBV, the Institute of Polymers Science and Technology (ICTP-CSIC), the University of Len, the University of Vigo, the University of Mlaga, the National Microelectronics Centre (CNM-CSIC), the Institute for Corpuscular Physics (IFIC-CSIC), the Institute of Ceramica Galicia, the Polytechnic University of Catalunya (UPC), PRODINTEC, INCAR, ICMM-CSIC, the University of Barcelona, the Bosch i Gimpera Foundation and the Chemical Institute of Sarri (IQS).

Carrying out this project will also enable fomenting synergies and reducing project development times through drawing up a joint-working framework between the various multidisciplinary players within the Science-Technology-Enterprise network. These players have knowledge and experience that complement each other and which are present throughout the whole value chain of the sector and, as a consequence, will give rise to enhanced competitiveness amongst the participating companies, thus reducing excessive external dependence, readdressing the unfavourable situation of our country as regards the transfer of research results by OPIs and CITs to companies in this field of advanced biomaterials, and improving the scientific-technical level of the enterprises taking part in the project. All this with the target of being in a more advantageous position to participate in international programmes of cooperation in scientific research and technological development, such as the FP VII.


'/>"/>

Contact: Irati Kortabitarte
iratik@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related biology news :

1. TECNALIA leads five projects within the VII Framework Program
2. Queens marine biologist investigates aliens beneath the waves
3. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
4. Embryonic stem cell strategy advanced with UCSF finding
5. Model for the assembly of advanced, single-molecule-based electronic components developed at Pitt
6. $1.1 million NSF grant to fund research in advanced light microscopy at UCLA
7. CSIC and UAB will build the most advanced superconductor cable for electricity network
8. Research at Argonnes Advanced Photon Source reveals structure and behavior of collagen
9. Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer
10. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
11. Combining advanced medical and information technologies offers pathway to lower health care costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology: